ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Association of pathological response with long-term survival after neoadjuvant chemo-immunotherapy in resectable oesophageal squamous cell carcinoma: a systematic review and individual-patient-data meta-analysis.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeNeoadjuvant chemo-immunotherapy increases pathological response rates in resectable oesophageal squamous cell carcinoma (ESCC), but the prognostic value of pathological complete response (pCR) and major pathological response (MPR), together with the optimal number of neoadjuvant cycles, remains uncertain. METHODS/PATIENTS: We performed a PRISMA-IPD-compliant systematic review and individual-patient-data (IPD) meta-analysis of studies published from 2018 to 30 April 2025. IPD were obtained from investigators or reconstructed from Kaplan-Meier curves. One-stage Cox models and random-effects pooling assessed associations of pCR and MPR with overall survival (OS), disease-free survival (DFS) and progression-free survival (PFS), and compared two versus three-four neoadjuvant cycles. The protocol was registered in PROSPERO (CRD420251027590).
resultsFourteen studies (n=2072) were included. pCR was associated with improved OS (HR 0.23, 95% CI 0.15-0.37) and DFS (HR 0.24, 95% CI 0.15-0.39), and with longer PFS (HR 0.20, 95% CI 0.05-0.84). MPR predicted superior OS (HR 0.32, 95% CI 0.17-0.60) and DFS (HR 0.38, 95% CI 0.25-0.57), with borderline significance for PFS (HR 0.49, 95% CI 0.23-1.03). In exploratory analyses, no clear survival difference was observed between two cycles and three-to-four neoadjuvant cycles.
conclusionsIn resectable ESCC treated with neoadjuvant chemo-immunotherapy, pCR and MPR are robust prognostic markers for OS and DFS, whereas the exploratory cycle-number analysis did not show a clear survival advantage for three-to-four cycles over two cycles.
Indexed as
Identifiers
42410274What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.